VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q42623641  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241120235739.0
008     241120nneanz||abbn n and d
035 ‎‡a  (WKP)Q42623641‏
024 ‎‡a  0000-0001-5418-3330‏ ‎‡2  orcid‏
024 ‎‡a  14626545100‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q42623641‏
100 0 ‎‡a  Daniel O'brien‏ ‎‡9  ast‏ ‎‡9  es‏ ‎‡9  sl‏
375 ‎‡a  1‏ ‎‡2  iso5218‏
400 0 ‎‡a  Daniel O'brien‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Daniel O'brien‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
670 ‎‡a  Author's A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers‏
670 ‎‡a  Author's Antibiotic Complications During the Treatment of Mycobacterium ulcerans Disease in Australian Patients‏
670 ‎‡a  Author's Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa?‏
670 ‎‡a  Author's Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age.‏
670 ‎‡a  Author's Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries‏
670 ‎‡a  Author's Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review‏
670 ‎‡a  Author's Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review‏
670 ‎‡a  Author's Causes of false-positive HIV rapid diagnostic test results‏
670 ‎‡a  Author's Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis‏
670 ‎‡a  Author's Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection‏
670 ‎‡a  Author's Clinical features and risk factors of oedematous Mycobacterium ulcerans lesions in an Australian population: beware cellulitis in an endemic area‏
670 ‎‡a  Author's Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans‏
670 ‎‡a  Author's Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings‏
670 ‎‡a  Author's Diagnosis of Mycobacterium ulcerans disease: be alert to the possibility of negative initial PCR results‏
670 ‎‡a  Author's Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population‏
670 ‎‡a  Author's Exposure Risk for Infection and Lack of Human-to-Human Transmission of Mycobacterium ulcerans Disease, Australia‏
670 ‎‡a  Author's False positive HIV diagnoses in resource limited settings: operational lessons learned for HIV programmes‏
670 ‎‡a  Author's Gastrointestinal infection among international travelers globally‏
670 ‎‡a  Author's Generating Evidence to Improve the Response to Neglected Diseases: How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management Guidance‏
670 ‎‡a  Author's HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo‏
670 ‎‡a  Author's Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach‏
670 ‎‡a  Author's Illness in returned travelers and immigrants/refugees: the 6-year experience of two Australian infectious diseases units‏
670 ‎‡a  Author's Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings‏
670 ‎‡a  Author's Implications of differentiated care for successful ART scale-up in a concentrated HIV epidemic in Yangon, Myanmar.‏
670 ‎‡a  Author's In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy‏
670 ‎‡a  Author's Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections‏
670 ‎‡a  Author's Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings‏
670 ‎‡a  Author's Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia‏
670 ‎‡a  Author's Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort‏
670 ‎‡a  Author's Long-term follow-up of schistosomiasis serology post-treatment in Australian travelers and immigrants‏
670 ‎‡a  Author's Low incidence of recurrent Buruli ulcers in treated Australian patients living in an endemic region‏
670 ‎‡a  Author's Malaria in travelers: a review of the GeoSentinel surveillance network.‏
670 ‎‡a  Author's Management of BU-HIV co-infection‏
670 ‎‡a  Author's Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?‏
670 ‎‡a  Author's Moxifloxacin for Buruli ulcer/HIV-coinfected patients: kill two birds with one stone? Author reply.‏
670 ‎‡a  Author's Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort‏
670 ‎‡a  Author's Mycobacterium ulcerans disease management in Australian patients: the re-emergence of surgery as an important treatment modality‏
670 ‎‡a  Author's Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes‏
670 ‎‡a  Author's Mycobacterium ulcerans infection: evolution in clinical management‏
670 ‎‡a  Author's Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?‏
670 ‎‡a  Author's Nontuberculous mycobacterial disease in northern Australia: a case series and review of the literature.‏
670 ‎‡a  Author's Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007.‏
670 ‎‡a  Author's Outpatient parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis: a retrospective cohort study‏
670 ‎‡a  Author's Paediatric Buruli ulcer in Australia‏
670 ‎‡a  Author's Pre-emptive steroids for a severe oedematous Buruli ulcer lesion: a case report‏
670 ‎‡a  Author's Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional study‏
670 ‎‡a  Author's Provision and continuation of antiretroviral therapy during acute conflict: the experience of MSF in Central African Republic and Yemen.‏
670 ‎‡a  Author's Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières‏
670 ‎‡a  Author's Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings‏
670 ‎‡a  Author's Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort‏
670 ‎‡a  Author's Risk factors for unstructured treatment interruptions and association with survival in low to middle income countries‏
670 ‎‡a  Author's Screening practices for infectious diseases among Burmese refugees in Australia‏
670 ‎‡a  Author's Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières‏
670 ‎‡a  Author's Serotonin syndrome due to co-administration of linezolid and venlafaxine‏
670 ‎‡a  Author's Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa‏
670 ‎‡a  Author's Spontaneous healing of Mycobacterium ulcerans disease in Australian patients‏
670 ‎‡a  Author's Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis‏
670 ‎‡a  Author's Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study‏
670 ‎‡a  Author's Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report‏
670 ‎‡a  Author's Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response‏
670 ‎‡a  Author's Teicoplanin hypersensitivity syndrome‏
670 ‎‡a  Author's The association of rainfall and Buruli ulcer in southeastern Australia‏
670 ‎‡a  Author's The changing epidemiology worldwide of Mycobacterium ulcerans‏
670 ‎‡a  Author's The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm.‏
670 ‎‡a  Author's The ‘frozen state’ of drug-resistant tuberculosis: notes from the field in Abkhazia‏
670 ‎‡a  Author's The location of Australian Buruli ulcer lesions-Implications for unravelling disease transmission.‏
670 ‎‡a  Author's The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa‏
670 ‎‡a  Author's Treatment costs of Mycobacterium ulcerans in the antibiotic era.‏
670 ‎‡a  Author's Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings‏
670 ‎‡a  Author's Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.‏
670 ‎‡a  Author's Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients‏
670 ‎‡a  Author's Universal access: the benefits and challenges in bringing integrated HIV care to isolated and conflict affected populations in the Republic of Congo.‏
670 ‎‡a  Author's Unlocking of the secrets of Mycobacterium ulcerans disease transmission‏
670 ‎‡a  Author's Variation in specificity of HIV rapid diagnostic tests over place and time: an analysis of discordancy data using a Bayesian approach.‏
670 ‎‡a  Author's Viral load testing in a resource-limited setting: quality control is critical‏
670 ‎‡a  Author's Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.‏
909 ‎‡a  (scopus) 14626545100‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000154183330‏ ‎‡9  1‏
919 ‎‡a  riskfactorsforunstructuredtreatmentinterruptionsandassociationwithsurvivalinlowtomiddleincomecountries‏ ‎‡A  Risk factors for unstructured treatment interruptions and association with survival in low to middle income countries‏ ‎‡9  1‏
919 ‎‡a  riskfactorsforrecurrentmycobacteriumulceransdiseaseafterexclusivesurgicaltreatmentinanaustraliancohort‏ ‎‡A  Risk factors for recurrent Mycobacterium ulcerans disease after exclusive surgical treatment in an Australian cohort‏ ‎‡9  1‏
919 ‎‡a  riskfactorsformortalityduringantiretroviraltherapyinolderpopulationsinresourcelimitedsettings‏ ‎‡A  Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings‏ ‎‡9  1‏
919 ‎‡a  provisionofantiretroviraltreatmentinconflictsettingstheexperienceofmedecinssansfrontieres‏ ‎‡A  Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières‏ ‎‡9  1‏
919 ‎‡a  provisionandcontinuationofantiretroviraltherapyduringacuteconflicttheexperienceofmsfincentralafricanrepublicandyemen‏ ‎‡A  Provision and continuation of antiretroviral therapy during acute conflict: the experience of MSF in Central African Republic and Yemen.‏ ‎‡9  1‏
919 ‎‡a  predictorsofraisedviralloadduringantiretroviraltherapyinpatientswithandwithoutpriorantiretroviraluseacrosssectionalstudy‏ ‎‡A  Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional study‏ ‎‡9  1‏
919 ‎‡a  preemptivesteroidsforasevereoedematousburuliulcerlesionacasereport‏ ‎‡A  Pre-emptive steroids for a severe oedematous Buruli ulcer lesion: a case report‏ ‎‡9  1‏
919 ‎‡a  paediatricburuliulcerinaustralia‏ ‎‡A  Paediatric Buruli ulcer in Australia‏ ‎‡9  1‏
919 ‎‡a  outpatientparenteralantimicrobialtherapyissafeandeffectiveforthetreatmentofinfectiveendocarditisaretrospectivecohortstudy‏ ‎‡A  Outpatient parenteral antimicrobial therapy is safe and effective for the treatment of infective endocarditis: a retrospective cohort study‏ ‎‡9  1‏
919 ‎‡a  outcomesofaremotedecentralizedhealthcenterbasedhivaidsantiretroviralprograminzambia2003to‏ ‎‡A  Outcomes of a remote, decentralized health center-based HIV/AIDS antiretroviral program in Zambia, 2003 to 2007.‏ ‎‡9  1‏
919 ‎‡a  nontuberculousmycobacterialdiseaseinnorthernaustraliaacaseseriesandreviewoftheliterature‏ ‎‡A  Nontuberculous mycobacterial disease in northern Australia: a case series and review of the literature.‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceranstreatmentcanantibioticdurationbereducedinselectedpatients‏ ‎‡A  Mycobacterium ulcerans treatment--can antibiotic duration be reduced in selected patients?‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceransinfectionevolutioninclinicalmanagement‏ ‎‡A  Mycobacterium ulcerans infection: evolution in clinical management‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceransintheelderlymoreseverediseaseandsuboptimaloutcomes‏ ‎‡A  Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceransdiseasemanagementinaustralianpatientsthereemergenceofsurgeryasanimportanttreatmentmodality‏ ‎‡A  Mycobacterium ulcerans disease management in Australian patients: the re-emergence of surgery as an important treatment modality‏ ‎‡9  1‏
919 ‎‡a  mycobacteriumulceransdiseaseexperiencewithprimaryoralmedicaltherapyinanaustraliancohort‏ ‎‡A  Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort‏ ‎‡9  1‏
919 ‎‡a  moxifloxacinforburuliulcerhivcoinfectedpatientskill2birdswith1stoneauthorreply‏ ‎‡A  Moxifloxacin for Buruli ulcer/HIV-coinfected patients: kill two birds with one stone? Author reply.‏ ‎‡9  1‏
919 ‎‡a  moxifloxacinforburuliulcerhivcoinfectedpatientskill2birdswith1stone‏ ‎‡A  Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?‏ ‎‡9  1‏
919 ‎‡a  managementofbuhivcoinfection‏ ‎‡A  Management of BU-HIV co-infection‏ ‎‡9  1‏
919 ‎‡a  malariaintravelersareviewofthegeosentinelsurveillancenetwork‏ ‎‡A  Malaria in travelers: a review of the GeoSentinel surveillance network.‏ ‎‡9  1‏
919 ‎‡a  lowincidenceofrecurrentburuliulcersintreatedaustralianpatientslivinginanendemicregion‏ ‎‡A  Low incidence of recurrent Buruli ulcers in treated Australian patients living in an endemic region‏ ‎‡9  1‏
919 ‎‡a  longtermfollowupofschistosomiasisserologyposttreatmentinaustraliantravelersandimmigrants‏ ‎‡A  Long-term follow-up of schistosomiasis serology post-treatment in Australian travelers and immigrants‏ ‎‡9  1‏
919 ‎‡a  increasingexperiencewithprimaryoralmedicaltherapyformycobacteriumulceransdiseaseinanaustraliancohort‏ ‎‡A  Increasing Experience with Primary Oral Medical Therapy for Mycobacterium ulcerans Disease in an Australian Cohort‏ ‎‡9  1‏
919 ‎‡a  increasedseverityandspreadofmycobacteriumulceranssoutheasternaustralia‏ ‎‡A  Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia‏ ‎‡9  1‏
919 ‎‡a  incidenceofwhostage3and4conditionsfollowinginitiationofantiretroviraltherapyinresourcelimitedsettings‏ ‎‡A  Incidence of WHO stage 3 and 4 conditions following initiation of anti-retroviral therapy in resource limited settings‏ ‎‡9  1‏
919 ‎‡a  incidenceclinicalspectrumdiagnosticfeaturestreatmentandpredictorsofparadoxicalreactionsduringantibiotictreatmentofmycobacteriumulceransinfections‏ ‎‡A  Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections‏ ‎‡9  1‏
919 ‎‡a  inresourcelimitedsettingsgoodearlyoutcomescanbeachievedinchildrenusingadultfixeddosecombinationantiretroviraltherapy‏ ‎‡A  In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy‏ ‎‡9  1‏
919 ‎‡a  implicationsofdifferentiatedcareforsuccessfulartscaleupinaconcentratedhivepidemicinyangonmyanmar‏ ‎‡A  Implications of differentiated care for successful ART scale-up in a concentrated HIV epidemic in Yangon, Myanmar.‏ ‎‡9  1‏
919 ‎‡a  impactofhivassociatedconditionsonmortalityinpeoplecommencingantiretroviraltherapyinresourcelimitedsettings‏ ‎‡A  Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings‏ ‎‡9  1‏
919 ‎‡a  illnessinreturnedtravelersandimmigrantsrefugeesthe6yearexperienceof2australianinfectiousdiseasesunits‏ ‎‡A  Illness in returned travelers and immigrants/refugees: the 6-year experience of two Australian infectious diseases units‏ ‎‡9  1‏
919 ‎‡a  ibrutinibandantimicrobialtherapyinaheavilypretreatedpatientwithchroniclymphocyticleukaemiaanddisseminatedcutaneousnontuberculousmycobacterialinfectionsuccessfulsurgeryfreeapproach‏ ‎‡A  Ibrutinib and antimicrobial therapy in a heavily pretreated patient with chronic lymphocytic leukaemia and disseminated cutaneous non-tuberculous mycobacterial infection: successful surgery-free approach‏ ‎‡9  1‏
919 ‎‡a  evaluationofarapidinsituhivconfirmationtestinaprogrammewithahighfailurerateofthewhohiv2testdiagnosticalgorithm‏ ‎‡A  The evaluation of a rapid in situ HIV confirmation test in a programme with a high failure rate of the WHO HIV two-test diagnostic algorithm.‏ ‎‡9  1‏
919 ‎‡a  hivtreatmentinaconflictsettingoutcomesandexperiencesfrombukavudemocraticrepublicofthecongo‏ ‎‡A  HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo‏ ‎‡9  1‏
919 ‎‡a  generatingevidencetoimprovetheresponsetoneglecteddiseaseshowoperationalresearchinamedecinssansfrontieresburuliulcertreatmentprogrammeinformedinternationalmanagementguidance‏ ‎‡A  Generating Evidence to Improve the Response to Neglected Diseases: How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management Guidance‏ ‎‡9  1‏
919 ‎‡a  gastrointestinalinfectionamonginternationaltravelersglobally‏ ‎‡A  Gastrointestinal infection among international travelers globally‏ ‎‡9  1‏
919 ‎‡a  falsepositivehivdiagnosesinresourcelimitedsettingsoperationallessonslearnedforhivprogrammes‏ ‎‡A  False positive HIV diagnoses in resource limited settings: operational lessons learned for HIV programmes‏ ‎‡9  1‏
919 ‎‡a  exposureriskforinfectionandlackofhumantohumantransmissionofmycobacteriumulceransdiseaseaustralia‏ ‎‡A  Exposure Risk for Infection and Lack of Human-to-Human Transmission of Mycobacterium ulcerans Disease, Australia‏ ‎‡9  1‏
919 ‎‡a  epidemiologyclinicalfeaturesanddiagnosisofmycobacteriumulceransinanaustralianpopulation‏ ‎‡A  Epidemiology, clinical features and diagnosis of Mycobacterium ulcerans in an Australian population‏ ‎‡9  1‏
919 ‎‡a  diagnosisofmycobacteriumulceransdiseasebealerttothepossibilityofnegativeinitialpcrresults‏ ‎‡A  Diagnosis of Mycobacterium ulcerans disease: be alert to the possibility of negative initial PCR results‏ ‎‡9  1‏
919 ‎‡a  costeffectivenessofroutineandlowcostcd4tcellcountcomparedwithwhoclinicalstagingofhivtoguideinitiationofantiretroviraltherapyinresourcelimitedsettings‏ ‎‡A  Cost-effectiveness of routine and low-cost CD4 T-cell count compared with WHO clinical staging of HIV to guide initiation of antiretroviral therapy in resource-limited settings‏ ‎‡9  1‏
919 ‎‡a  corticosteroiduseforparadoxicalreactionsduringantibiotictreatmentformycobacteriumulcerans‏ ‎‡A  Corticosteroid use for paradoxical reactions during antibiotic treatment for Mycobacterium ulcerans‏ ‎‡9  1‏
919 ‎‡a  clinicalfeaturesandriskfactorsofoedematousmycobacteriumulceranslesionsinanaustralianpopulationbewarecellulitisinanendemicarea‏ ‎‡A  Clinical features and risk factors of oedematous Mycobacterium ulcerans lesions in an Australian population: beware cellulitis in an endemic area‏ ‎‡9  1‏
919 ‎‡a  clinicalfeaturesandmanagementofasevereparadoxicalreactionassociatedwithcombinedtreatmentofburuliulcerandhivcoinfection‏ ‎‡A  Clinical features and management of a severe paradoxical reaction associated with combined treatment of Buruli ulcer and HIV co-infection‏ ‎‡9  1‏
919 ‎‡a  causesofhospitaladmissionamongpeoplelivingwithhivworldwideasystematicreviewandmetaanalysis‏ ‎‡A  Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis‏ ‎‡9  1‏
919 ‎‡a  causesoffalsepositivehivrapiddiagnostictestresults‏ ‎‡A  Causes of false-positive HIV rapid diagnostic test results‏ ‎‡9  1‏
919 ‎‡a  candidaglabrataprostheticvalveendocarditistreatedsuccessfullywithfluconazolepluscaspofunginwithoutsurgeryacasereportandliteraturereview‏ ‎‡A  Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review‏ ‎‡9  1‏
919 ‎‡a  burdenofhivrelatedcytomegalovirusretinitisinresourcelimitedsettingsasystematicreview‏ ‎‡A  Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review‏ ‎‡9  1‏
919 ‎‡a  associationbetweenolderageandadverseoutcomesonantiretroviraltherapyacohortanalysisofprogrammedatafrom9countries‏ ‎‡A  Association between older age and adverse outcomes on antiretroviral therapy: a cohort analysis of programme data from nine countries‏ ‎‡9  1‏
919 ‎‡a  antiretroviraltherapyoutcomesinresourcelimitedsettingsforhivinfectedchildren5yearsofage‏ ‎‡A  Antiretroviral therapy outcomes in resource-limited settings for HIV-infected children <5 years of age.‏ ‎‡9  1‏
919 ‎‡a  antiretroviraltherapyforhivpreventionmanyconcernsandchallengesbutaretherewaysforwardinsubsaharanafrica‏ ‎‡A  Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa?‏ ‎‡9  1‏
919 ‎‡a  antibioticcomplicationsduringthetreatmentofmycobacteriumulceransdiseaseinaustralianpatients‏ ‎‡A  Antibiotic Complications During the Treatment of Mycobacterium ulcerans Disease in Australian Patients‏ ‎‡9  1‏
919 ‎‡a  globalstudyofpathogensandhostriskfactorsassociatedwithinfectiousgastrointestinaldiseaseinreturnedinternationaltravellers‏ ‎‡A  A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers‏ ‎‡9  1‏
919 ‎‡a  treatmentoutcomesstratifiedbybaselineimmunologicalstatusamongyoungchildrenreceivingnonnucleosidereversetranscriptaseinhibitorbasedantiretroviraltherapyinresourcelimitedsettings‏ ‎‡A  Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings‏ ‎‡9  1‏
919 ‎‡a  variationinspecificityofhivrapiddiagnostictestsoverplaceandtimeananalysisofdiscordancydatausingabayesianapproach‏ ‎‡A  Variation in specificity of HIV rapid diagnostic tests over place and time: an analysis of discordancy data using a Bayesian approach.‏ ‎‡9  1‏
919 ‎‡a  frozenstateofdrugresistanttuberculosisnotesfromthefieldinabkhazia‏ ‎‡A  The ‘frozen state’ of drug-resistant tuberculosis: notes from the field in Abkhazia‏ ‎‡9  1‏
919 ‎‡a  viralloadtestinginaresourcelimitedsettingqualitycontroliscritical‏ ‎‡A  Viral load testing in a resource-limited setting: quality control is critical‏ ‎‡9  1‏
919 ‎‡a  woundhealingnaturalhistoryandriskfactorsfordelayinaustralianpatientstreatedwithantibioticsformycobacteriumulceransdisease‏ ‎‡A  Wound healing: Natural history and risk factors for delay in Australian patients treated with antibiotics for Mycobacterium ulcerans disease.‏ ‎‡9  1‏
919 ‎‡a  locationofaustralianburuliulcerlesionsimplicationsforunravellingdiseasetransmission‏ ‎‡A  The location of Australian Buruli ulcer lesions-Implications for unravelling disease transmission.‏ ‎‡9  1‏
919 ‎‡a  tuberculosisafterhaartinitiationinhivpositivepatientsfrom5countrieswithahightuberculosisburden‏ ‎‡A  Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.‏ ‎‡9  1‏
919 ‎‡a  understandingoflatenttuberculosisitstreatmentandtreatmentsideeffectsinimmigrantandrefugeepatients‏ ‎‡A  Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients‏ ‎‡9  1‏
919 ‎‡a  universalaccessthebenefitsandchallengesinbringingintegratedhivcaretoisolatedandconflictaffectedpopulationsintherepublicofcongo‏ ‎‡A  Universal access: the benefits and challenges in bringing integrated HIV care to isolated and conflict affected populations in the Republic of Congo.‏ ‎‡9  1‏
919 ‎‡a  urgentneedforclinicaldiagnosticandoperationalresearchformanagementofburuliulcerinafrica‏ ‎‡A  The urgent need for clinical, diagnostic, and operational research for management of Buruli ulcer in Africa‏ ‎‡9  1‏
919 ‎‡a  treatmentcostsofmycobacteriumulceransintheantibioticera‏ ‎‡A  Treatment costs of Mycobacterium ulcerans in the antibiotic era.‏ ‎‡9  1‏
919 ‎‡a  unlockingofthesecretsofmycobacteriumulceransdiseasetransmission‏ ‎‡A  Unlocking of the secrets of Mycobacterium ulcerans disease transmission‏ ‎‡9  1‏
919 ‎‡a  changingepidemiologyworldwideofmycobacteriumulcerans‏ ‎‡A  The changing epidemiology worldwide of Mycobacterium ulcerans‏ ‎‡9  1‏
919 ‎‡a  associationofrainfallandburuliulcerinsoutheasternaustralia‏ ‎‡A  The association of rainfall and Buruli ulcer in southeastern Australia‏ ‎‡9  1‏
919 ‎‡a  teicoplaninhypersensitivitysyndrome‏ ‎‡A  Teicoplanin hypersensitivity syndrome‏ ‎‡9  1‏
919 ‎‡a  tacklingtheworseningepidemicofburuliulcerinaustraliainaninformationvoidtimeforanurgentscientificresponse‏ ‎‡A  Tackling the worsening epidemic of Buruli ulcer in Australia in an information void: time for an urgent scientific response‏ ‎‡9  1‏
919 ‎‡a  successfultreatmentofmycobacteriumulceransosteomyelitiswithminorsurgicaldebridementandprolongedrifampicinandciprofloxacintherapyacasereport‏ ‎‡A  Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report‏ ‎‡9  1‏
919 ‎‡a  successfuloutcomeswithoralfluoroquinolonescombinedwithrifampicininthetreatmentofmycobacteriumulceransanobservationalcohortstudy‏ ‎‡A  Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study‏ ‎‡9  1‏
919 ‎‡a  staphylococcusaureusbacteraemiaevaluationoftheroleoftransoesophagealechocardiographyinidentifyingclinicallyunsuspectedendocarditis‏ ‎‡A  Staphylococcus aureus bacteraemia: evaluation of the role of transoesophageal echocardiography in identifying clinically unsuspected endocarditis‏ ‎‡9  1‏
919 ‎‡a  spontaneoushealingofmycobacteriumulceransdiseaseinaustralianpatients‏ ‎‡A  Spontaneous healing of Mycobacterium ulcerans disease in Australian patients‏ ‎‡9  1‏
919 ‎‡a  similarmortalityandreducedlosstofollowupinintegratedcomparedwithverticalprogramsprovidingantiretroviraltreatmentinsubsaharanafrica‏ ‎‡A  Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa‏ ‎‡9  1‏
919 ‎‡a  serotoninsyndromeduetocoadministrationoflinezolidandvenlafaxine‏ ‎‡A  Serotonin syndrome due to co-administration of linezolid and venlafaxine‏ ‎‡9  1‏
919 ‎‡a  2lineantiretroviraltherapyinresourcelimitedsettingstheexperienceofmedecinssansfrontieres‏ ‎‡A  Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières‏ ‎‡9  1‏
919 ‎‡a  screeningpracticesforinfectiousdiseasesamongburmeserefugeesinaustralia‏ ‎‡A  Screening practices for infectious diseases among Burmese refugees in Australia‏ ‎‡9  1‏
943 ‎‡a  200x‏ ‎‡A  2007‏ ‎‡9  1‏
946 ‎‡a  b‏ ‎‡9  1‏
996 ‎‡2  NTA|163079951‏
996 ‎‡2  SUDOC|030189829‏
996 ‎‡2  SUDOC|274427869‏
996 ‎‡2  SUDOC|029815355‏
996 ‎‡2  ISNI|0000000506281867‏
996 ‎‡2  CAOONL|ncf10280492‏
996 ‎‡2  SUDOC|168096129‏
996 ‎‡2  ISNI|0000000351464449‏
996 ‎‡2  N6I|vtls000027714‏
996 ‎‡2  BNF|16997486‏
996 ‎‡2  N6I|vtls000303149‏
996 ‎‡2  ISNI|0000000496276828‏
996 ‎‡2  ISNI|0000000447273516‏
996 ‎‡2  J9U|987012383979905171‏
996 ‎‡2  ISNI|0000000500393286‏
996 ‎‡2  BNF|17978909‏
996 ‎‡2  NLA|000036011393‏
996 ‎‡2  J9U|987007409740505171‏
996 ‎‡2  ISNI|0000000049722945‏
996 ‎‡2  LC|no2012043282‏
996 ‎‡2  J9U|987007431976005171‏
996 ‎‡2  ISNI|000000050449632X‏
996 ‎‡2  DNB|1147208263‏
996 ‎‡2  BIBSYS|49051‏
996 ‎‡2  LC|no2004097632‏
996 ‎‡2  ISNI|0000000065322132‏
996 ‎‡2  CAOONL|ncf11333463‏
996 ‎‡2  SUDOC|234393246‏
996 ‎‡2  ISNI|0000000496222555‏
996 ‎‡2  SUDOC|086060686‏
996 ‎‡2  J9U|987007277139505171‏
996 ‎‡2  J9U|987007439219205171‏
996 ‎‡2  LC|n 90603442‏
996 ‎‡2  N6I|vtls000029092‏
996 ‎‡2  LC|n 2004104876‏
996 ‎‡2  NTA|087837838‏
996 ‎‡2  BNF|14424112‏
996 ‎‡2  J9U|987010305266105171‏
996 ‎‡2  ISNI|0000000127681166‏
996 ‎‡2  LC|no2017154444‏
996 ‎‡2  ISNI|0000000043474346‏
996 ‎‡2  SUDOC|244914664‏
996 ‎‡2  BNF|12495630‏
996 ‎‡2  N6I|vtls002622068‏
996 ‎‡2  LC|no2023056655‏
996 ‎‡2  LC|nr2007003239‏
996 ‎‡2  ISNI|0000000498898612‏
996 ‎‡2  NII|DA05617052‏
996 ‎‡2  CAOONL|ncf10252212‏
996 ‎‡2  NII|DA15412158‏
996 ‎‡2  BIBSYS|90840895‏
996 ‎‡2  NSK|000668450‏
996 ‎‡2  LC|n 85281473‏
996 ‎‡2  BNF|12096636‏
996 ‎‡2  ISNI|0000000434829693‏
996 ‎‡2  CAOONL|ncf10721511‏
996 ‎‡2  DNB|1226262368‏
996 ‎‡2  LC|no2014054565‏
996 ‎‡2  ISNI|0000000090961454‏
996 ‎‡2  J9U|987007426211305171‏
996 ‎‡2  LC|n 2018024592‏
996 ‎‡2  LC|no2022130599‏
996 ‎‡2  CAOONL|ncf10434767‏
996 ‎‡2  LC|no2018069501‏
996 ‎‡2  LC|no2019099548‏
996 ‎‡2  DNB|1147177856‏
996 ‎‡2  LC|n 2004100194‏
996 ‎‡2  J9U|987007329025005171‏
996 ‎‡2  DNB|1212882350‏
996 ‎‡2  DNB|171101804‏
996 ‎‡2  SUDOC|029313988‏
996 ‎‡2  SUDOC|079113265‏
996 ‎‡2  RERO|A011525164‏
996 ‎‡2  NUKAT|n 2019201599‏
996 ‎‡2  NUKAT|n 2015197875‏
996 ‎‡2  DNB|171431170‏
996 ‎‡2  LIH|LNB:_p_B_b_;=B_k_‏
996 ‎‡2  LC|nb2003042185‏
996 ‎‡2  DNB|171715500‏
996 ‎‡2  CAOONL|ncf10723597‏
996 ‎‡2  SUDOC|273001302‏
996 ‎‡2  NDL|00723889‏
996 ‎‡2  ISNI|0000000114069242‏
996 ‎‡2  BNF|15060568‏
996 ‎‡2  CAOONL|ncf11617361‏
996 ‎‡2  LC|nr2005003066‏
996 ‎‡2  ISNI|000000006747720X‏
996 ‎‡2  J9U|987007447941005171‏
996 ‎‡2  ISNI|0000000499334317‏
996 ‎‡2  NTA|306060086‏
996 ‎‡2  LC|no2006119335‏
996 ‎‡2  ISNI|0000000118562085‏
996 ‎‡2  ISNI|0000000114709633‏
996 ‎‡2  NUKAT|n 2006095686‏
996 ‎‡2  ISNI|0000000084015824‏
996 ‎‡2  LC|n 91107109‏
996 ‎‡2  ISNI|0000000433427342‏
996 ‎‡2  BIBSYS|1697005479117‏
996 ‎‡2  SUDOC|110834518‏
996 ‎‡2  N6I|vtls002710215‏
996 ‎‡2  J9U|987007319674305171‏
996 ‎‡2  CAOONL|ncf11426102‏
996 ‎‡2  ISNI|0000000382309230‏
996 ‎‡2  DNB|130466433‏
996 ‎‡2  ISNI|0000000040938061‏
996 ‎‡2  LC|nb2019021310‏
996 ‎‡2  ISNI|0000000430343047‏
996 ‎‡2  BIBSYS|90056908‏
996 ‎‡2  PLWABN|9811492645505606‏
996 ‎‡2  PTBNP|1564959‏
996 ‎‡2  CAOONL|ncf11239580‏
996 ‎‡2  BIBSYS|90183762‏
996 ‎‡2  ISNI|0000000075483474‏
996 ‎‡2  BIBSYS|2034529‏
996 ‎‡2  ISNI|0000000050446773‏
996 ‎‡2  J9U|987007406236905171‏
996 ‎‡2  ISNI|000000003255878X‏
996 ‎‡2  ISNI|0000000043024046‏
996 ‎‡2  NUKAT|n 01044232‏
996 ‎‡2  LC|no2010140138‏
996 ‎‡2  N6I|vtls002175943‏
996 ‎‡2  DNB|129982512‏
996 ‎‡2  DNB|1143853008‏
996 ‎‡2  BNF|15525147‏
996 ‎‡2  ISNI|0000000055471353‏
996 ‎‡2  DNB|134369292X‏
996 ‎‡2  ISNI|0000000121479573‏
996 ‎‡2  LC|n 2006028498‏
996 ‎‡2  CAOONL|ncf11964931‏
996 ‎‡2  N6I|vtls000308535‏
996 ‎‡2  BNE|XX4448116‏
996 ‎‡2  BNF|17705695‏
996 ‎‡2  W2Z|1697005479117‏
996 ‎‡2  BIBSYS|90943284‏
996 ‎‡2  BNF|17997178‏
996 ‎‡2  BNF|12136191‏
996 ‎‡2  NDL|00472416‏
996 ‎‡2  NUKAT|n 00714241‏
996 ‎‡2  NKC|mzk2007423767‏
996 ‎‡2  NKC|jo2016921260‏
996 ‎‡2  SUDOC|116762373‏
996 ‎‡2  DNB|1207184225‏
996 ‎‡2  NII|DA00489294‏
996 ‎‡2  LC|no2022031134‏
996 ‎‡2  LC|no 96033792‏
996 ‎‡2  ISNI|0000000117963821‏
996 ‎‡2  LC|n 2014007344‏
996 ‎‡2  LC|no2009037168‏
996 ‎‡2  LC|n 88647995‏
996 ‎‡2  LIH|LNB:DRH3;=_z_W‏
996 ‎‡2  NKC|vse20191059247‏
996 ‎‡2  DNB|1112346414‏
996 ‎‡2  LC|n 83184722‏
996 ‎‡2  ISNI|0000000065537854‏
996 ‎‡2  NTA|298336898‏
996 ‎‡2  RERO|A012478818‏
996 ‎‡2  ISNI|0000000083285072‏
996 ‎‡2  LC|no2008186905‏
996 ‎‡2  LC|n 87847758‏
996 ‎‡2  DNB|1213309603‏
996 ‎‡2  NKC|xx0316328‏
996 ‎‡2  NII|DA13236983‏
996 ‎‡2  BIBSYS|9012560‏
996 ‎‡2  DNB|143446762‏
996 ‎‡2  DNB|173893058‏
996 ‎‡2  NUKAT|n 2014090365‏
996 ‎‡2  LC|n 79033907‏
996 ‎‡2  PLWABN|9810535447005606‏
996 ‎‡2  LC|n 2015039324‏
996 ‎‡2  SUDOC|195443675‏
996 ‎‡2  ISNI|0000000033021802‏
996 ‎‡2  N6I|vtls000038601‏
996 ‎‡2  DNB|132141116‏
996 ‎‡2  LC|n 97048534‏
996 ‎‡2  DNB|104922292X‏
996 ‎‡2  LC|n 99282522‏
996 ‎‡2  NSK|000501199‏
996 ‎‡2  DNB|1169682154‏
996 ‎‡2  LC|n 2019072331‏
996 ‎‡2  NUKAT|n 2007094790‏
996 ‎‡2  LC|no2011034440‏
996 ‎‡2  ISNI|0000000118561963‏
996 ‎‡2  DNB|126315798X‏
996 ‎‡2  NTA|074226746‏
996 ‎‡2  ISNI|0000000051456666‏
996 ‎‡2  N6I|vtls002849033‏
996 ‎‡2  LC|n 85142748‏
996 ‎‡2  CAOONL|ncf10443886‏
996 ‎‡2  SZ|1207184225‏
996 ‎‡2  DNB|1286459664‏
996 ‎‡2  LC|n 80015897‏
996 ‎‡2  SUDOC|034171258‏
996 ‎‡2  J9U|987007386646305171‏
996 ‎‡2  ISNI|0000000394534574‏
996 ‎‡2  NTA|408833165‏
996 ‎‡2  BIBSYS|90329994‏
996 ‎‡2  LC|nb2017001375‏
996 ‎‡2  NII|DA05527288‏
996 ‎‡2  ISNI|0000000367524979‏
996 ‎‡2  BIBSYS|90562448‏
996 ‎‡2  LC|n 2014045386‏
996 ‎‡2  ISNI|0000000047599576‏
996 ‎‡2  LC|n 2019185047‏
996 ‎‡2  N6I|vtls000075986‏
996 ‎‡2  DNB|132646560‏
996 ‎‡2  ISNI|0000000072938824‏
996 ‎‡2  N6I|vtls002660265‏
996 ‎‡2  LC|no2017061514‏
996 ‎‡2  LC|n 97060973‏
996 ‎‡2  BIBSYS|99015731‏
996 ‎‡2  PLWABN|9810701421905606‏
996 ‎‡2  LC|n 86007472‏
996 ‎‡2  LC|no2008156881‏
996 ‎‡2  LC|n 2020048293‏
996 ‎‡2  RERO|A003649247‏
996 ‎‡2  DNB|135077850‏
996 ‎‡2  NLA|000036015147‏
996 ‎‡2  CAOONL|ncf10291988‏
996 ‎‡2  NUKAT|n 99028813‏
996 ‎‡2  LC|no2010007415‏
996 ‎‡2  N6I|vtls000054723‏
996 ‎‡2  DBC|87097969630057‏
996 ‎‡2  N6I|vtls000273276‏
996 ‎‡2  NDL|00899115‏
996 ‎‡2  PLWABN|9810664066205606‏
996 ‎‡2  ISNI|0000000121368347‏
996 ‎‡2  SUDOC|079917283‏
996 ‎‡2  LC|no2008089790‏
996 ‎‡2  LC|no2004021614‏
996 ‎‡2  LC|n 2019011545‏
996 ‎‡2  NII|DA19116124‏
996 ‎‡2  J9U|987007266019705171‏
996 ‎‡2  LC|n 94105973‏
996 ‎‡2  DNB|1208729934‏
996 ‎‡2  CAOONL|ncf10123161‏
996 ‎‡2  NTA|068522258‏
996 ‎‡2  LC|n 85156761‏
996 ‎‡2  ISNI|0000000043892249‏
996 ‎‡2  LC|nb2008007195‏
996 ‎‡2  LC|no2014014996‏
996 ‎‡2  LC|no2009095030‏
996 ‎‡2  NTA|072867019‏
996 ‎‡2  ISNI|0000000434302859‏
996 ‎‡2  BIBSYS|4012733‏
996 ‎‡2  SUDOC|254011470‏
996 ‎‡2  BNF|12165672‏
996 ‎‡2  RERO|A003649250‏
996 ‎‡2  RERO|A003649251‏
996 ‎‡2  ISNI|0000000058055662‏
996 ‎‡2  BNE|XX1051056‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏